Abstract
The aim of the present article is to discuss the potential of gene therapy for thymic hormones as a novel therapeutic strategy to treat dyshomeostatic conditions associated with congenital athymia or hypofunction of the endocrine thymus. Recent studies using an adenoviral vector harboring a synthetic gene for the thymic peptide thymulin are reviewed. This adenoviral vector was injected intramuscularly in thymectomized and nude mice as well as in thymectomized rats. Transduced myocytes acted as an ectopic source of thymulin thus restoring circulating thymulin levels to normal values. This restorative effect was long lasting (several months) even though an adenoviral vector was used. In the rat brain, adenovirally-mediated delivery of the synthetic gene for thymulin achieved longer expression than in the case of adenovirally-delivered reporter genes, which is consistent with the reported antiinflammatory activity of thymulin in the brain. Furthermore, neonatal thymulin gene therapy in nude female mice was able to prevent the pituitary and ovarian alterations that typically occur in this mutant after puberty. Neonatal thymulin gene therapy in nude mice was able to prevent some of the alterations in lipid metabolism that develop during adult life in congenitally athymic mice. We conclude that the availability of the above biotechnological tools should boost basic studies on the molecular biology of thymulin and should also allow an assessment of the potential of gene therapy to restore circulating thymulin levels in thymodeficient animal models and eventually, in humans.
Keywords: Thymus-pituitary axis, thymulin, synthetic gene, nude-reproductive derangements, lipids, antiinflammatory therapy
Current Gene Therapy
Title: Potential of Gene Therapy for Restoration of Endocrine Thymic Function in Thymus-Deficient Animal Models
Volume: 8 Issue: 1
Author(s): Gustavo R. Morel, Paula C. Reggiani, Gloria M. Console, Omar J. Rimoldi, Silvan M. Vesenbeckh, Margarita M. Garcia-Bravo, Silvia S. Rodriguez, Oscar A. Brown and Rodolfo G. Goya
Affiliation:
Keywords: Thymus-pituitary axis, thymulin, synthetic gene, nude-reproductive derangements, lipids, antiinflammatory therapy
Abstract: The aim of the present article is to discuss the potential of gene therapy for thymic hormones as a novel therapeutic strategy to treat dyshomeostatic conditions associated with congenital athymia or hypofunction of the endocrine thymus. Recent studies using an adenoviral vector harboring a synthetic gene for the thymic peptide thymulin are reviewed. This adenoviral vector was injected intramuscularly in thymectomized and nude mice as well as in thymectomized rats. Transduced myocytes acted as an ectopic source of thymulin thus restoring circulating thymulin levels to normal values. This restorative effect was long lasting (several months) even though an adenoviral vector was used. In the rat brain, adenovirally-mediated delivery of the synthetic gene for thymulin achieved longer expression than in the case of adenovirally-delivered reporter genes, which is consistent with the reported antiinflammatory activity of thymulin in the brain. Furthermore, neonatal thymulin gene therapy in nude female mice was able to prevent the pituitary and ovarian alterations that typically occur in this mutant after puberty. Neonatal thymulin gene therapy in nude mice was able to prevent some of the alterations in lipid metabolism that develop during adult life in congenitally athymic mice. We conclude that the availability of the above biotechnological tools should boost basic studies on the molecular biology of thymulin and should also allow an assessment of the potential of gene therapy to restore circulating thymulin levels in thymodeficient animal models and eventually, in humans.
Export Options
About this article
Cite this article as:
Morel R. Gustavo, Reggiani C. Paula, Console M. Gloria, Rimoldi J. Omar, Vesenbeckh M. Silvan, Garcia-Bravo M. Margarita, Rodriguez S. Silvia, Brown A. Oscar and Goya G. Rodolfo, Potential of Gene Therapy for Restoration of Endocrine Thymic Function in Thymus-Deficient Animal Models, Current Gene Therapy 2008; 8 (1) . https://dx.doi.org/10.2174/156652308783688518
DOI https://dx.doi.org/10.2174/156652308783688518 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Efficacy of High-Dose Vitamin D Supplementation in the Critically Ill Patients
Inflammation & Allergy - Drug Targets (Discontinued) Anti-inflammatory, Antioxidant, Lung and Liver Protective Activity of <i>Galaxaura oblongata</i> as Antagonistic Efficacy against LPS using Hematological Parameters and Immunohistochemistry as Biomarkers
Cardiovascular & Hematological Agents in Medicinal Chemistry Zinc and its Specific Transporters as Potential Targets in Airway Disease
Current Drug Targets Proniosomes in Transdermal Drug Delivery
Current Pharmaceutical Design Indoleamine 2,3-dioxygenase (IDO): Biology and Target in Cancer Immunotherapies
Current Cancer Drug Targets Functional Genomics of the Oxidative Stress Pathway
Current Hypertension Reviews Disease-Related Changes in TRPV1 Expression and Its Implications for Drug Development
Current Topics in Medicinal Chemistry Telomerase Modulation in Therapeutic Approach
Current Pharmaceutical Design Natural Steroids and Androgen Antagonists used as Neuroprotection in Common Neurological Disorders
CNS & Neurological Disorders - Drug Targets Recent Approaches for Studying the Role of Glia
CNS & Neurological Disorders - Drug Targets β-Glucuronidase Inhibitory Studies on Coumarin Derivatives
Medicinal Chemistry Cardiovascular and Systemic Risk in Nonalcoholic Fatty Liver Disease - Atherosclerosis as a Major Player in the Natural Course of NAFLD
Current Pharmaceutical Design Current Challenges to Overcome in the Management of Type 2 Diabetes Mellitus and Associated Neurological Disorders
CNS & Neurological Disorders - Drug Targets Modulators of Acetylcholinesterase Activity: From Alzheimer's Disease to Anti-Cancer Drugs
Current Medicinal Chemistry Pulmonary and Nasal Anti-Inflammatory and Anti-Allergy Inhalation Aerosol Delivery Systems
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Melanin-Concentrating Hormone Receptor 1 Antagonists: A New Perspective for the Pharmacologic Treatment of Obesity
Current Medicinal Chemistry Molecular and Biochemical Features in Alzheimers Disease
Current Pharmaceutical Design Drug-induced Cardiac Mitochondrial Toxicity and Protection: From Doxorubicin to Carvedilol
Current Pharmaceutical Design Clinical, Genetic, and Neuroimaging Features of Early Onset Alzheimer Disease: The Challenges of Diagnosis and Treatment
Current Alzheimer Research Hijacking the Hedgehog Pathway in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry